Cover Image

Randomized comparison of cardiotoxicity with 60 versus 90 mg daunorubicin in AML induction therapy

Anthracyclines are an essential component of induction therapy for acute myeloid leukemia (AML), but their optimal dosing and the associated risk for cardiotoxicity remain under debate. The DaunoDouble trial compared daunorubicin at 60 (Dauno60) versus 90 mg/m2 (Dauno90) in combination with cytarabi...

Full description

Saved in:
Bibliographic Details
Main Authors: Dendorfer, Stefan Markus (Author) , Schmidt-Brücken, Katharina (Author) , Kramer, Michael (Author) , Steffen, Björn (Author) , Schliemann, Christoph (Author) , Mikesch, Jan-Henrik (Author) , Alakel, Nael (Author) , Herbst, Regina (Author) , Hänel, Mathias (Author) , Hanoun, Maher (Author) , Kaufmann, Martin (Author) , Weinbergerova, Barbora (Author) , Schäfer-Eckart, Kerstin (Author) , Sauer, Tim (Author) , Neubauer, Andreas (Author) , Burchert, Andreas (Author) , Baldus, Claudia D. (Author) , Mertová, Jolana (Author) , Jost, Edgar (Author) , Niemann, Dirk (Author) , Novák, Jan (Author) , Krause, Stefan W. (Author) , Scholl, Sebastian (Author) , Hochhaus, Andreas (Author) , Held, Gerhard (Author) , Szotkowski, Tomáš (Author) , Rank, Andreas (Author) , Schmid, Christoph (Author) , Fransecky, Lars (Author) , Kayser, Sabine (Author) , Schaich, Markus (Author) , Fiebig, Frank (Author) , Haake, Annett (Author) , Schetelig, Johannes (Author) , Middeke, Jan Moritz (Author) , Stölzel, Friedrich (Author) , Platzbecker, Uwe (Author) , Thiede, Christian (Author) , Müller-Tidow, Carsten (Author) , Berdel, Wolfgang E. (Author) , Ehninger, Gerhard (Author) , Mayer, Jiri (Author) , Serve, Hubert (Author) , Bornhäuser, Martin (Author) , Röllig, Christoph (Author)
Format: Article (Journal)
Language:English
Published: March 2026
In: American journal of hematology
Year: 2026, Volume: 101, Issue: 3, Pages: 512-520
ISSN:1096-8652
DOI:10.1002/ajh.70160
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1002/ajh.70160
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.70160
Get full text
Author Notes:Stefan Markus Dendorfer, Katharina Schmidt-Brücken, Michael Kramer, Björn Steffen, Christoph Schliemann, Jan-Henrik Mikesch, Nael Alakel, Regina Herbst, Mathias Hänel, Maher Hanoun, Martin Kaufmann, Barbora Weinbergerova, Kerstin Schäfer-Eckart, Tim Sauer, Andreas Neubauer, Andreas Burchert, Claudia D. Baldus, Jolana Mertová, Edgar Jost, Dirk Niemann, Jan Novák, Stefan W. Krause, Sebastian Scholl, Andreas Hochhaus, Gerhard Held, Tomáš Szotkowski, Andreas Rank, Christoph Schmid, Lars Fransecky, Sabine Kayser, Markus Schaich, Frank Fiebig, Annett Haake, Johannes Schetelig, Jan Moritz Middeke, Friedrich Stölzel, Uwe Platzbecker, Christian Thiede, Carsten Müller-Tidow, Wolfgang E. Berdel, Gerhard Ehninger, Jiri Mayer, Hubert Serve, Martin Bornhäuser, Christoph Röllig
Description
Summary:Anthracyclines are an essential component of induction therapy for acute myeloid leukemia (AML), but their optimal dosing and the associated risk for cardiotoxicity remain under debate. The DaunoDouble trial compared daunorubicin at 60 (Dauno60) versus 90 mg/m2 (Dauno90) in combination with cytarabine (100 mg/m2 for 7 days) in newly diagnosed AML patients aged 18-65 years. Cardiac function was assessed by left ventricular ejection fraction (LVEF) and cardiac biomarkers (high-sensitivity troponin T [hsTnT], NT-proBNP) before treatment and on Day 15 in 317 randomized patients. Median LVEF declined significantly from 65% [IQR 60%-68.5%] to 61% [IQR 58%-67.8%] across all patients (p < 0.01), without significant differences between treatment arms. NT-proBNP levels measured after induction therapy correlated negatively with LVEF at the same time point (ρ = −0.24, p = 0.02), but did not change significantly during induction—neither between Day 1 and 15 nor between treatment arms. HsTnT levels increased significantly from 5 [IQR 4-8] to 8 ng/L [IQR 6-14] across all patients (p < 0.01), with higher post-induction values in the Dauno90 group (9.5 ng/L [IQR 7-14]) compared to Dauno60 (7 ng/L [IQR 5-14]; p < 0.01). In exploratory subgroup analyses, post-induction hsTnT levels were also significantly higher in patients with obesity and arterial hypertension. These findings provide evidence of a dose-dependent cardiotoxic effect of daunorubicin, already apparent at standard induction doses, and underscore the importance of early cardiac monitoring. Long-term follow-up will be essential to determine the clinical significance of these early changes. Trial Registration: ClinicalTrials.gov identifier: NCT02140242
Item Description:Erstmals veröffentlicht: 5. Januar 2026
Gesehen am 05.02.2026
Physical Description:Online Resource
ISSN:1096-8652
DOI:10.1002/ajh.70160

Similar Items